MTOR and bladder transitional cell carcinoma: However, thus far, clinical trials limiting mTOR activity have shown limited efficacy52, but studies using novel mTOR targeting agents or a combination of agents are ongoing and may identify formulations that can effectively limit BlCa tumorigenesis.